Pharvaris N.V. (PHVS)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Berndt Axel Edvard Modig CPA, M.B.A.
|
Co-Founder, CEO & Executive Director | 1.54M | -- | 1959 |
|
Dr. Peng Lu M.D., Ph.D.
|
President | -- | -- | 1978 |
|
Mr. David W. Nassif J.D.
|
CFO, Chief Legal Officer & Corporate Secretary | -- | -- | 1954 |
|
Ms. Anna Nijdam M.Sc., R.A.
|
Head of Strategic Finance & Principal Accounting Officer | -- | -- | 1981 |
|
Dr. Stefan Abele Ph.D.
|
Chief Technology Operations Officer | -- | -- | 1970 |
|
Ms. Annick Deschoolmeester
|
Chief Human Resources Officer | -- | -- | 1973 |
|
Dr. Anne A. Lesage Ph.D.
|
Chief Early Development Officer | -- | -- | 1961 |
|
Mr. Wim Souverijns Ph.D.
|
Chief Commercial Officer | -- | -- | 1971 |
|
Maggie Beller
|
VP & Head of Corporate and Investor Communications | -- | -- | -- |
|
Maryann Cimino
|
Director of Corporate Relations | -- | -- | -- |
Pharvaris N.V.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 148
Description
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Corporate Governance
Upcoming Events
November 12, 2026 at 1:30 PM UTC
Pharvaris N.V. Earnings Date
Recent Events
September 23, 2025 at 12:00 AM UTC
POSASR: Post-effective Amendment to an automatic shelf registration statement on Form S-3ASR or Form F- 3ASR
